arrow
M

Mario Sznol

Ruprecht Karls University Heidelberg
H指数:12
被引数:467

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Non-invasive profiling of the tumour microenvironment with spatial ecotypes

无创性空间生态型表征肿瘤微环境

Nature
IF48.5
2026-05-060
OAAI
Bridging the gap: A systematic approach to integrating serum and plasma proteomic datasets for biomarker studies

弥合差距:一种整合血清和血浆蛋白质组学数据集用于生物标志物研究的系统性方法

2026-02-010
OAAI
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
2023-08-0310
OAAI
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

M9241 (NHS-IL12) 联合阿维鲁单抗在晚期实体瘤患者中的首次人类Ib期试验,包括晚期尿路上皮癌患者的剂量扩展

2023-05-269
OAAI
Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis (vol 13, 898, 2022)
2022-05-102
OAAI
Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis
2022-02-2329
OAAI
PHASE II OF CD40 AGONISTIC ANTIBODY SOTIGALIMAB (APX005M) IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH METASTATIC MELANOMA WITH CONFIRMED DISEASE PROGRESSION ON ANTI-PD-1 THERAPY
2021-11-105
OA